Bionomics Reports Topline Results in PREVAIL Phase 2 Study

BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary EndpointSubjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward...

Related Keywords

Adelaide ,South Australia ,Australia ,United States ,Canada ,Americans ,Kevin Gardner ,Spyridon Spyro Papapetropoulos ,Suzanne Irwin ,Connor Bernstein ,Merck Co Inc ,Company Is Continuing Analysis Of The Data ,Corporate Development ,Bionomics Limited Nasdaq ,Nasdaq ,Bionomics Or Company ,Social Anxiety Disorder ,Did Not Meet Primary ,Favourable Safety ,Tolerability Profile Consistent ,Continuing Analysis ,Evaluating Next Steps ,Cash Runway ,Subjective Units ,Distress Scale ,Public Speaking Challenge ,Errol De Souza ,Executive Chairman ,Spyro Papapetropoulos ,Liebowitz Social Anxiety Scale ,State Trait Anxiety Inventory ,Negative Self Statements During Public Speaking ,Post Traumatic Stress Disorder ,Nasdaq Bnox ,Bionomics Ltd ,Biotech ,Nc210 ,Social Anxiety ,Ns ,Ptsd ,